IMC.AX - Immuron Limited

ASX - ASX Delayed Price. Currency in AUD
0.2500
0.0000 (0.00%)
At close: 10:06AM AEDT
Stock chart is not supported by your current browser
Previous Close0.2500
Open0.2550
Bid0.25 x 0
Ask0.27 x 0
Day's Range0.2500 - 0.2550
52 Week Range0.2000 - 0.6000
Volume10,098
Avg. Volume54,960
Market Cap35.804M
Beta (3Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.26
  • GlobeNewswire16 days ago

    Immuron Receives $1.19M R&D Tax Concession Refund

    MELBOURNE, Australia, Jan. 08, 2019 -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and.

  • One Thing To Remember About The Immuron Limited (ASX:IMC) Share Price
    Simply Wall St.2 months ago

    One Thing To Remember About The Immuron Limited (ASX:IMC) Share Price

    If you own shares in Immuron Limited (ASX:IMC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • GlobeNewswire2 months ago

    Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO

    NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of Synergy Pharmaceuticals Inc. a Nasdaq-listed public biopharmaceutical company located in New York, NY focused on the development of drugs to treat gastrointestinal disorders and diseases.

  • GlobeNewswire2 months ago

    NASH clinical trial presentation and continued revenue growth

    Australian Travelan® sales continue to grow, with a Q1 CY19 figure of $340K AUD. Global Immuron Limited sales for Q1 2019 reached $482K AUD which is a 2% increase on the same quarter of last financial year. NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study of Liver Disease which will be held in San Francisco, California during the 9th – 13th of November 2018.

  • Could Immuron Limited’s (ASX:IMC) Investor Composition Impacts Your Returns?
    Simply Wall St.4 months ago

    Could Immuron Limited’s (ASX:IMC) Investor Composition Impacts Your Returns?

    If you want to know who really controls Immuron Limited (ASX:IMC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...